Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Rodriguez

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
Cancer Research|May 2, 2019
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in <i>KRAS</i>-Mutant Lung AdenocarcinomaAna Galan-Cobo, Piyada Sitthideatphaiboon, Xiao Qu, et al.
Journal for Immunotherapy of Cancer|December 20, 2017
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironmentSusanne M Steggerda, Mark K Bennett, Jason Chen, et al.
Molecular Cancer Therapeutics|February 14, 2014
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancerMatt I Gross, Susan D Demo, Jennifer B Dennison, et al.
BMC Cancer|December 3, 2022
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) studyL de la Cruz-Merino, M Gion, J Cruz, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
Cancer Research|May 2, 2019
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in <i>KRAS</i>-Mutant Lung AdenocarcinomaAna Galan-Cobo, Piyada Sitthideatphaiboon, Xiao Qu, et al.
Journal for Immunotherapy of Cancer|December 20, 2017
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironmentSusanne M Steggerda, Mark K Bennett, Jason Chen, et al.
Molecular Cancer Therapeutics|February 14, 2014
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancerMatt I Gross, Susan D Demo, Jennifer B Dennison, et al.
BMC Cancer|December 3, 2022
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) studyL de la Cruz-Merino, M Gion, J Cruz, et al.
Pageof 10